NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today the CE marking of Eve™, a critical congenital heart disease (CCHD) newborn screening application, for the Rad-97™ Pulse ...
NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced Dual SET ® Pulse Oximetry for Root ®, a highly versatile patient monitoring and connectivity hub. The first application ...
Masimo’s revolutionary SET® pulse oximetry has been shown in more than 100 independent and objective studies to outperform other pulse oximetry technologies – even before the revisions that achieved ...
Masimo Corporation MASI recently announced the publication of the results of a prospective study in the Sri Lanka Journal of Child Health, demonstrating the efficacy of using Masimo Signal Extraction ...
About a year after beginning its full market launch, Masimo’s W1 smartwatch can now be used as a medical device in the U.S. The wearable device has earned FDA clearance for its medical applications, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results